Judith M. Boer

7.2k total citations · 2 hit papers
94 papers, 4.7k citations indexed

About

Judith M. Boer is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Judith M. Boer has authored 94 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Molecular Biology, 42 papers in Public Health, Environmental and Occupational Health and 28 papers in Hematology. Recurrent topics in Judith M. Boer's work include Acute Lymphoblastic Leukemia research (42 papers), Chronic Myeloid Leukemia Treatments (23 papers) and Gene expression and cancer classification (14 papers). Judith M. Boer is often cited by papers focused on Acute Lymphoblastic Leukemia research (42 papers), Chronic Myeloid Leukemia Treatments (23 papers) and Gene expression and cancer classification (14 papers). Judith M. Boer collaborates with scholars based in Netherlands, Germany and United States. Judith M. Boer's co-authors include Renée X. de Menezes, Gert‐Jan B. van Ommen, H. Berna Beverloo, Johan T. den Dunnen, Peter A.C. ’t Hoen, Gerard C. Grosveld, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Peter J.M. Valk, Michael Moorhouse and Ruud Delwel and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Judith M. Boer

89 papers receiving 4.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia

2004 997 citations Judith M. Boer, H. Berna Beverloo et al. profile →
Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms

2008 617 citations Renée X. de Menezes, Judith M. Boer et al. Nucleic Acids Research profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Judith M. Boer	2.7k	1.1k	713	658	652	94	4.7k
Toshiya Inaba	2.6k 1.0×	1.7k 1.5×	492 0.7×	653 1.0×	605 0.9×	124	4.6k
Ursula R. Kees	2.4k 0.9×	989 0.9×	489 0.7×	1.3k 2.0×	876 1.3×	138	4.8k
Kazuhiro Morishita	2.7k 1.0×	1.3k 1.1×	430 0.6×	1.2k 1.8×	301 0.5×	143	4.9k
Min Fang	1.8k 0.7×	1.7k 1.5×	403 0.6×	437 0.7×	837 1.3×	182	4.7k
Rolf Marschalek	3.3k 1.2×	2.0k 1.8×	412 0.6×	395 0.6×	1.4k 2.1×	225	5.4k
Renée X. de Menezes	2.4k 0.9×	721 0.6×	982 1.4×	333 0.5×	887 1.4×	84	4.1k
Michael Cross	1.7k 0.6×	910 0.8×	568 0.8×	623 0.9×	226 0.3×	136	3.9k
Pieter Van Vlierberghe	2.7k 1.0×	1.2k 1.1×	1.5k 2.1×	604 0.9×	1.3k 2.0×	113	4.5k
Yoshinobu Matsuo	1.7k 0.6×	972 0.9×	346 0.5×	1.0k 1.5×	348 0.5×	126	3.7k
Xiaoyan Jiang	1.7k 0.6×	1.9k 1.7×	397 0.6×	782 1.2×	306 0.5×	151	4.4k

Countries citing papers authored by Judith M. Boer

Since Specialization

Citations

This map shows the geographic impact of Judith M. Boer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith M. Boer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith M. Boer more than expected).

Fields of papers citing papers by Judith M. Boer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith M. Boer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith M. Boer. The network helps show where Judith M. Boer may publish in the future.

Co-authorship network of co-authors of Judith M. Boer

This figure shows the co-authorship network connecting the top 25 collaborators of Judith M. Boer. A scholar is included among the top collaborators of Judith M. Boer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith M. Boer. Judith M. Boer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boeree, Aurélie, et al.. (2025). Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia. HemaSphere. 9(1). e70069–e70069. 2 indexed citations

Tasian, Sarah K., Judith M. Boer, & Monique L. den Boer. (2025). From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents. PubMed. 6. 100304–100304.

Boer, Judith M., Marco J. Koudijs, Lennart Kester, et al.. (2025). Challenging Conventional Diagnostic Methods by Comprehensive Molecular Diagnostics: A Nationwide Prospective Comparison in Children With ALL. JCO Precision Oncology. 9(9). e2400788–e2400788. 1 indexed citations

Boeree, Aurélie, Edwin Sonneveld, Anthony V. Moorman, et al.. (2025). IGH rearrangements in Down syndrome acute lymphoblastic leukemia. SHILAP Revista de lepidopterología. 5. 100223–100223. 1 indexed citations

Boer, Judith M., Aurélie Boeree, Karin P.S. Langenberg, et al.. (2024). Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience. HemaSphere. 8(7). e122–e122.

Das, Mili, Suzanne E. Hile, Judith M. Boer, et al.. (2024). DNA polymerase zeta can efficiently replicate structures formed by AT/TA repeat sequences and prevent their deletion. Nucleic Acids Research. 53(3). 2 indexed citations

Trifinopoulos, Jana, Thorsten Klampfl, Klara R. Klein, et al.. (2024). Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress responses. Haematologica. 110(4). 877–892.

Boer, Judith M., Cesca van de Ven, Aurélie Boeree, et al.. (2024). Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations. Blood Advances. 8(8). 1835–1845. 1 indexed citations

Hoogerbrugge, Peter M., Judith M. Boer, Edwin Sonneveld, et al.. (2024). ABL-Class Fusion Gene Induced Pediatric CML Presenting As ALL. Blood. 144(Supplement 1). 5851–5851. 1 indexed citations

10.

Boer, Judith M., et al.. (2024). IKZF1 in acute lymphoblastic leukemia: the rise before the fall?. Leukemia & lymphoma. 65(14). 2077–2087. 3 indexed citations

11.

Boeree, Aurélie, Edwin Sonneveld, Anthony V. Moorman, et al.. (2023). Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations. SHILAP Revista de lepidopterología. 3. 100140–100140. 2 indexed citations

12.

Boeree, Aurélie, Cesca van de Ven, Gabriele Escherich, et al.. (2023). Secondary Lesions and Sensitivity to Signaling Inhibitors of Pediatric iAMP21 B-Cell Precursor Acute Lymphoblastic Leukemia. Blood. 142(Supplement 1). 1613–1613. 1 indexed citations

13.

Pieters, Rob, Hester de Groot‐Kruseman, Marta Fiocco, et al.. (2023). Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups. Journal of Clinical Oncology. 41(25). 4130–4142. 25 indexed citations

14.

Boeree, Aurélie, et al.. (2023). Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb. Frontiers in Oncology. 13. 1128560–1128560. 3 indexed citations

15.

Padilla, Laura, Judith M. Boer, Melanie M. Hagleitner, et al.. (2022). Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement. Cancers. 14(16). 3895–3895. 6 indexed citations

16.

Witkowski, Matthew T., Yifang Hu, Kathryn G. Roberts, et al.. (2017). Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome. The Journal of Experimental Medicine. 214(3). 773–791. 22 indexed citations

17.

Iterson, Maarten van, Floor A.M. Duijkers, Jules P.P. Meijerink, et al.. (2012). A Novel and Fast Normalization Method for High-Density Arrays. Statistical Applications in Genetics and Molecular Biology. 11(4). 2 indexed citations

18.

Cardoso, Joana, Renée X. de Menezes, Monique E. van Leerdam, et al.. (2006). Chromosomal Instability in MYH - and APC -Mutant Adenomatous Polyps. Cancer Research. 66(5). 2514–2519. 45 indexed citations

19.

Boer, Judith M., Wolfgang Huber, Holger Sültmann, et al.. (2001). Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31,500-Element cDNA Array. Genome Research. 11(11). 1861–1870. 157 indexed citations

20.

Beißbarth, Tim, Kurt Fellenberg, Benedikt Brors, et al.. (2000). Processing and quality control of DNA array hybridization data. Bioinformatics. 16(11). 1014–1022. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact